Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 183821, 7 pages
http://dx.doi.org/10.1155/2015/183821
Research Article

Determination of Serum Lost Goodwill Target Proteome in Patients with Severe Traumatic Brain Injury

1Department of Neurosurgery, Shanxi Provincial People’s Hospital, Taiyuan 030001, China
2Department of Neurosurgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
3Department of Neurosurgery, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China
4Department of Neurosurgery, Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China

Received 8 March 2015; Revised 26 July 2015; Accepted 28 July 2015

Academic Editor: Aijun Wang

Copyright © 2015 Hongming Ji et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. D. Nichol and D. J. Cooper, “Can we improve neurological outcomes in severe traumatic brain injury? Something old (early prophylactic hypothermia) and something new (erythropoietin),” Injury, vol. 40, no. 5, pp. 471–478, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. G. W. Hergenroeder, J. B. Redell, A. N. Moore, and P. K. Dash, “Biomarkers in the clinical diagnosis and management of traumatic brain injury,” Molecular Diagnosis and Therapy, vol. 12, no. 6, pp. 345–358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. D. Timmons, “An update on traumatic brain injuries,” Journal of Neurosurgical Sciences, vol. 56, no. 3, pp. 191–202, 2012. View at Google Scholar · View at Scopus
  4. P. M. Kochanek, H. Bramlett, W. D. Dietrich et al., “A novel multicenter preclinical drug screening and biomarker consortium for experimental traumatic brain injury: operation brain trauma therapy,” The Journal of Trauma—Injury Infection & Critical Care, vol. 71, no. 1, supplement, pp. S15–S24, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. D. V. Agoston, A. Gyorgy, O. Eidelman, and H. B. Pollard, “Proteomic biomarkers for blast neurotrauma: targeting cerebral edema, inflammation, and neuronal death cascades,” Journal of Neurotrauma, vol. 26, no. 6, pp. 901–911, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. D. V. Agoston and M. Elsayed, “Serum-based protein biomarkers in blast-induced traumatic brain injury spectrum disorder,” Frontiers in Neurology, vol. 3, article 107, Article ID Article 107, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. D. A. Prieto, X. Ye, and T. D. Veenstra, “Proteomic analysis of traumatic brain injury: the search for biomarkers,” Expert Review of Proteomics, vol. 5, no. 2, pp. 283–291, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Pei, S. Guo, Q. Wang et al., “The first observation of the clinical significance of LGT proteome for cancer patients,” Cancer Research and Clinic, vol. 17, no. 3, pp. 156–158, 2005. View at Google Scholar
  9. P. Yi, S. Guo, Q. Wang et al., “A newly discovered fingerprint of functional proteome,” Zhongliu Yanjiu Yu Lingchuang, vol. 17, no. 3, pp. 153–155, 2005. View at Google Scholar
  10. P. Yi, “Discovery and concluding of characteristics of prewarning proteome fingerprints which mark prognostic of malignant tumor,” Shanxi Science and Technology Agency, vol. 193, p. 11, 2005. View at Google Scholar
  11. J. R. Ren, G. L. Zhang, H. M. Ji et al., “The clinical signifiance change of serumLGT proteome in patients with traumatic brain injury: a pilot study,” Zhongguo Yaowu Yu Lingchuang, vol. 10, no. 10, pp. 1095–1097, 2010. View at Google Scholar
  12. T. Gemoll, U. J. Roblick, G. Auer, H. Jörnvall, and J. K. Habermann, “SELDI-TOF serum proteomics and colorectal cancer: a current overview,” Archives of Physiology and Biochemistry, vol. 116, no. 4-5, pp. 188–196, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Seibert, M. P. A. Ebert, and T. Buschmann, “Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery,” Briefings in Functional Genomics and Proteomics, vol. 4, no. 1, pp. 16–26, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. A. B. da Rocha, R. F. Schneider, G. R. de Freitas et al., “Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males,” Clinical Chemistry and Laboratory Medicine, vol. 44, no. 10, pp. 1234–1242, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. S. J. I. Sandler, A. A. Figaji, and P. D. Adelson, “Clinical applications of biomarkers in pediatric traumatic brain injury,” Child's Nervous System, vol. 26, no. 2, pp. 205–213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. J. E. Risdall and D. K. Menon, “Traumatic brain injury,” Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 366, no. 1562, pp. 241–250, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. K. K. W. Wang, A. K. Ottens, M. C. Liu et al., “Proteomic identification of biomarkers of traumatic brain injury,” Expert Review of Proteomics, vol. 2, no. 4, pp. 603–614, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. P. M. Kochanek, R. P. Berger, H. Bayir, A. K. Wagner, L. W. Jenkins, and R. S. B. Clark, “Biomarkers of primary and evolving damage in traumatic and ischemic brain injury: diagnosis, prognosis, probing mechanisms, and therapeutic decision making,” Current Opinion in Critical Care, vol. 14, no. 2, pp. 135–141, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Li, H. C. Liu, G. L. Zhang et al., “Determination of serum neuron-specific enolase (NSE) in patients with severe traumatic brain injury,” Acta Medicinae Universitatis Scientiae et Technologiae Huazhong, vol. 40, no. 2, pp. 225–228, 2011. View at Google Scholar
  20. A. Chiaretti, G. Barone, R. Riccardi et al., “NGF, DCX, and NSE upregulation correlates with severity and outcome of head trauma in children,” Neurology, vol. 72, no. 7, pp. 609–616, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Woertgen, R. D. Rothoerl, and A. Brawanski, “Neuron-specific enolase serum levels after controlled cortical impact injury in the rat,” Journal of Neurotrauma, vol. 18, no. 5, pp. 569–573, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. A. E. Böhmer, J. P. Oses, A. P. Schmidt et al., “Neuron-specific enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury,” Neurosurgery, vol. 68, no. 6, pp. 1624–1630, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. S. M. Bloomfield, J. McKinney, L. Smith, and J. Brisman, “Reliability of S100B in predicting severity of central nervous system injury,” Neurocritical Care, vol. 6, no. 2, pp. 121–138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Kövesdi, J. Lückl, P. Bukovics et al., “Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics,” Acta Neurochirurgica, vol. 152, no. 1, pp. 1–17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Sofijanova, K. Piperkova, and D. Al Khalili, “Predicting outcome after severe brain injury in risk neonates using the serum S100B biomarker: results using single (24h) time-point,” Prilozi, vol. 33, no. 1, pp. 147–156, 2012. View at Google Scholar
  26. M. E. Carr Jr., L. N. Masullo, J. K. Brown, and P. C. Lewis, “Creatine kinase BB isoenzyme blood levels in trauma patients with suspected mild traumatic brain injury,” Military Medicine, vol. 174, no. 6, pp. 622–625, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Schiff, N. Hadker, S. Weiser, and C. Rausch, “A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury,” Molecular Diagnosis and Therapy, vol. 16, no. 2, pp. 79–92, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. K.-Y. Wang, G.-F. Yu, Z.-Y. Zhang, Q. Huang, and X.-Q. Dong, “Plasma high-mobility group box 1 levels and prediction of outcome in patients with traumatic brain injury,” Clinica Chimica Acta, vol. 413, no. 21–23, pp. 1737–1741, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Rodríguez-Rodríguez, J. J. Egea-Guerrero, A. León-Justel et al., “Role of S100B protein in urine and serum as an early predictor of mortality after severe traumatic brain injury in adults,” Clinica Chimica Acta, vol. 414, pp. 228–233, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Rainey, M. Lesko, R. Sacho, F. Lecky, and C. Childs, “Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: results using a single (24h) time-point,” Resuscitation, vol. 80, no. 3, pp. 341–345, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Mondello, A. Linnet, A. Buki et al., “Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury,” Neurosurgery, vol. 70, no. 3, pp. 666–675, 2012. View at Google Scholar · View at Scopus
  32. S. Mondello, L. Papa, A. Buki et al., “Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study,” Critical Care, vol. 15, no. 3, article R156, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. D. M. Stein, A. L. Lindel, K. R. Murdock, J. A. Kufera, J. Menaker, and T. M. Scalea, “Use of serum biomarkers to predict secondary insults following severe traumatic brain injury,” Shock, vol. 37, no. 6, pp. 563–568, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. F. M. S. Soares, N. M. de Souza, M. L. Schwarzbold et al., “Interleukin-10 is an independent biomarker of severe traumatic brain injury prognosis,” NeuroImmunoModulation, vol. 19, no. 6, pp. 377–385, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Macher, J. J. Egea-Guerrero, J. Revuelto-Rey et al., “Role of early cell-free DNA levels decrease as a predictive marker of fatal outcome after severe traumatic brain injury,” Clinica Chimica Acta, vol. 414, pp. 12–17, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. J.-R. Ren, H.-M. Ji, J.-M. Ji, J.-H. Feng, G.-L. Zhang, and H.-W. Zhang, “The clinical significance of the relationship between serum lost goodwill target proteome and the acute physiology and chronic health evaluation II score of patient with critical illness,” Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, vol. 23, no. 3, pp. 134–137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. J. R. Ren, G. L. Zhang, H. M. Ji et al., “The clinical significance of the serum LGT proteome for patients with traumatic brain injury,” Zhonghua Shiyuan Waike Zhazhi, vol. 28, no. 6, pp. 1001–1002, 2011. View at Google Scholar
  38. A. L. Bulman and E. A. Dalmasso, “Purification and identification of candidate biomarkers discovered using SELDI-TOF MS,” Methods in Molecular Biology, vol. 818, pp. 49–66, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. S. C. Karatayli, S. G. Alagöz, D. Mizrak et al., “Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS,” Turkish Journal of Gastroenterology, vol. 23, no. 1, pp. 46–53, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Li, D. Zhang, and C. Guo, “Serum biomarker screening for the diagnosis of early gastric cancer using SELDI-TOF-MS,” Molecular Medicine Reports, vol. 5, no. 6, pp. 1531–1535, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Menascu, A. Brezner, S. M. Tshechmer, and P. G. Rumeny, “Serum biochemical markers for brain damage in children with emphasis on mild head injury,” Pediatric Neurosurgery, vol. 46, no. 2, pp. 82–88, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. B. A. Stoica and A. I. Faden, “Cell death mechanisms and modulation in traumatic brain injury,” Neurotherapeutics, vol. 7, no. 1, pp. 3–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. A. M. Cook, A. Peppard, and B. Magnuson, “Nutrition considerations in traumatic brain injury,” Nutrition in Clinical Practice, vol. 23, no. 6, pp. 608–620, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. J.-F. Feng, X. Zhao, G. G. Gurkoff, K. C. Van, K. Shahlaie, and B. G. Lyeth, “Post-traumatic hypoxia exacerbates neuronal cell death in the hippocampus,” Journal of Neurotrauma, vol. 29, no. 6, pp. 1167–1179, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. I. Cernak and L. J. Noble-Haeusslein, “Traumatic brain injury: an overview of pathobiology with emphasis on military populations,” Journal of Cerebral Blood Flow and Metabolism, vol. 30, no. 2, pp. 255–266, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. J. J. Donkin and R. Vink, “Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments,” Current Opinion in Neurology, vol. 23, no. 3, pp. 293–299, 2010. View at Publisher · View at Google Scholar · View at Scopus